Spinal dorsal rami injection and radiofrequency neurolysis for low back pain caused by osteoporosis-induced thoracolumbar vertebral compression fractures
DOI:
https://doi.org/10.2340/20030711-1000056Keywords:
spinal dorsal rami injection, radiofrequency neurolysis, low back pain, thoracolumbar vertebral compression fractures, osteoporosisAbstract
Objective: Low back pain caused by osteoporosis-induced thoracolumbar vertebral compression fractures is a common debilitating disorder. The aims of this study were to determine the accuracy and efficacy of spinal dorsal ramus injection and radiofrequency neurolysis for pain reduction in patients with this condition. Methods: This study was a retrospective chart review of 46 patients with low back pain caused by osteoporosis-induced thoracolumbar vertebral compression fractures. All patients had been treated with spinal dorsal ramus injection with mixed Sensorcaine (Fresenius Kabi, USA) and Depo-Medrol (Pfizer, USA). In some patients further treatment with radiofrequency neurolysis had been required after the initial injection wore off. Results: Out of a total of 46 patients, 45 (97.7%) had ??50% reduction in low back pain immediately after injection. After the initial injection wore off, 18 patients remained pain free and 27 required radiofrequency neurolysis. The follow-up period ranged from 60 to 1,440 days (mean 335 days). The intensity of low back pain decreased from 7.09???0.84 (numerical pain scale of 0?10) before treatment to 1.39???1.51 immediately after the injection, and to 0.96???1.36 at the last office visit. Conclusion: Spinal dorsal ramus injection and radio-frequency neurolysis are effective and accurate therapies for low back pain caused by osteoporosis-induced thoracolumbar vertebral compression fractures.Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Linqiu Zhou, Jeffrey Zhou
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles in JRM-CC are Open Access and, unless otherwise specified, distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.